ERBB2 and breast carcinoma: Given this information, there has been a surge of research in the area of HER2-positive breast cancer, studying new mechanisms of anti-tumor drug delivery (i.e. T-DM1), as well as novel therapeutic combinations (i.e. trastuzumab, pertuzumab and docetaxel).